表紙
市場調査レポート

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:製品パイプライン分析

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 314194
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:製品パイプライン分析 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
出版日: 2016年08月24日 ページ情報: 英文 36 Pages
概要

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. は生物医薬品を研究、開発、製造、および製品化しています。その製品には、遺伝子工学薬、光線力学療法薬、リポゾーム薬、医療用診断製品などがあります。

当レポートでは、Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.の基本情報

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.の概要
  • 主要情報
  • 企業情報

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:R&Dの概要

  • 主な治療範囲

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:薬剤プロファイル

  • rhLT28-171
  • Hitenercept
  • rhPTH 1-34
  • vincristine sulfate liposomal
  • Fderceptin
  • Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:最近のパイプライン動向

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • Nifeviroc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08132CDB

Summary

Global Markets Direct's, 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • The report provides overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Snapshot
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Drug Profiles
    • aminolevulinic acid hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hitenercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-0001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Fderceptin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD30 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Analysis
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Target
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Projects
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Nifeviroc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Information
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Key Facts
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase II, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Phase I, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Unknown, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top